Apixaban Fails Phase III Knee Surgery Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Partnership with Pfizer cushions blow to Bristol-Myers’ new blood thinner.
You may also be interested in...
Bristol/Pfizer's Apixaban Bests Lovenox At Preventing VTE In Knee Surgery In Second Attempt
After failing to show non-inferiority in ADVANCE I, the Bristol/Pfizer anticoagulant was soundly superior to enoxaparin in ADVANCE II.
Bristol/Pfizer's Apixaban Bests Lovenox At Preventing VTE In Knee Surgery In Second Attempt
After failing to show non-inferiority in ADVANCE I, the Bristol/Pfizer anticoagulant was soundly superior to enoxaparin in ADVANCE II.
Bristol/Pfizer's Apixaban Bests Lovenox At Preventing VTE In Second Attempt
With the positive results of the ADVANCE II study of Bristol-Myers Squibb/Pfizer's apixaban now offsetting the failed non-inferiority of the earlier ADVANCE I study, the ADVANCE III study is shaping up to be the tie-breaker for how the investigational anticoagulant stacks up against Sanofi-Aventis' low molecular weight heparin Lovenox (enoxaparin) in patients undergoing orthopedic surgery